vs
PNC金融服务集团（PFIS）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
PNC金融服务集团的季度营收约是REGENXBIO Inc.的1.5倍（$46.8M vs $30.3M），PNC金融服务集团净利率更高（27.8% vs -221.3%，领先249.2%），REGENXBIO Inc.同比增速更快（43.0% vs 5.8%），PNC金融服务集团自由现金流更多（$43.3M vs $-52.8M），过去两年PNC金融服务集团的营收复合增速更高（43.5% vs 39.4%）
PNC金融服务集团是一家总部位于美国宾夕法尼亚州匹兹堡的银行控股与金融服务企业，旗下核心子公司PNC银行业务覆盖美国27个州及华盛顿哥伦比亚特区，拥有2629家分支机构与9523台ATM，按资产、网点数量、存款规模及ATM数量计算，是美国规模顶尖的银行之一。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PFIS vs RGNX — 直观对比
营收规模更大
PFIS
是对方的1.5倍
$30.3M
营收增速更快
RGNX
高出37.2%
5.8%
净利率更高
PFIS
高出249.2%
-221.3%
自由现金流更多
PFIS
多$96.1M
$-52.8M
两年增速更快
PFIS
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $46.8M | $30.3M |
| 净利润 | $12.0M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 31.5% | -190.0% |
| 净利率 | 27.8% | -221.3% |
| 营收同比 | 5.8% | 43.0% |
| 净利润同比 | 96.7% | -31.2% |
| 每股收益（稀释后） | $1.20 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PFISRGNX
| Q4 25 | $46.8M | $30.3M | ||
| Q3 25 | $46.7M | $29.7M | ||
| Q2 25 | $48.4M | $21.4M | ||
| Q1 25 | $45.8M | $89.0M | ||
| Q4 24 | $44.2M | $21.2M | ||
| Q3 24 | $45.0M | $24.2M | ||
| Q2 24 | $22.5M | $22.3M | ||
| Q1 24 | $22.7M | $15.6M |
净利润PFISRGNX
| Q4 25 | $12.0M | $-67.1M | ||
| Q3 25 | $15.2M | $-61.9M | ||
| Q2 25 | $17.0M | $-70.9M | ||
| Q1 25 | $15.0M | $6.1M | ||
| Q4 24 | $6.1M | $-51.2M | ||
| Q3 24 | $-4.3M | $-59.6M | ||
| Q2 24 | $3.3M | $-53.0M | ||
| Q1 24 | $3.5M | $-63.3M |
毛利率PFISRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率PFISRGNX
| Q4 25 | 31.5% | -190.0% | ||
| Q3 25 | 40.4% | -176.3% | ||
| Q2 25 | 42.2% | -296.3% | ||
| Q1 25 | 39.8% | 13.6% | ||
| Q4 24 | 13.2% | -242.1% | ||
| Q3 24 | -11.1% | -256.6% | ||
| Q2 24 | 16.5% | -251.3% | ||
| Q1 24 | 17.4% | -408.8% |
净利率PFISRGNX
| Q4 25 | 27.8% | -221.3% | ||
| Q3 25 | 32.7% | -208.3% | ||
| Q2 25 | 35.0% | -331.8% | ||
| Q1 25 | 32.8% | 6.8% | ||
| Q4 24 | 15.8% | -241.3% | ||
| Q3 24 | -9.6% | -246.3% | ||
| Q2 24 | 14.6% | -237.7% | ||
| Q1 24 | 15.3% | -405.4% |
每股收益（稀释后）PFISRGNX
| Q4 25 | $1.20 | $-1.30 | ||
| Q3 25 | $1.51 | $-1.20 | ||
| Q2 25 | $1.68 | $-1.38 | ||
| Q1 25 | $1.49 | $0.12 | ||
| Q4 24 | $0.47 | $-0.99 | ||
| Q3 24 | $-0.43 | $-1.17 | ||
| Q2 24 | $0.46 | $-1.05 | ||
| Q1 24 | $0.49 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $519.8M | $102.7M |
| 总资产 | $5.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PFISRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益PFISRGNX
| Q4 25 | $519.8M | $102.7M | ||
| Q3 25 | $509.3M | $161.5M | ||
| Q2 25 | $494.1M | $213.7M | ||
| Q1 25 | $481.9M | $274.2M | ||
| Q4 24 | $468.9M | $259.7M | ||
| Q3 24 | $475.1M | $301.4M | ||
| Q2 24 | $340.8M | $348.3M | ||
| Q1 24 | $340.0M | $390.7M |
总资产PFISRGNX
| Q4 25 | $5.3B | $453.0M | ||
| Q3 25 | $5.2B | $525.2M | ||
| Q2 25 | $5.1B | $581.0M | ||
| Q1 25 | $5.0B | $490.9M | ||
| Q4 24 | $5.1B | $466.0M | ||
| Q3 24 | $5.4B | $519.1M | ||
| Q2 24 | $3.6B | $569.4M | ||
| Q1 24 | $3.7B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $54.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $43.3M | $-52.8M |
| 自由现金流率自由现金流/营收 | 92.7% | -174.0% |
| 资本支出强度资本支出/营收 | 23.4% | 1.7% |
| 现金转化率经营现金流/净利润 | 4.53× | — |
| 过去12个月自由现金流最近4个季度 | $73.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流PFISRGNX
| Q4 25 | $54.3M | $-52.3M | ||
| Q3 25 | $15.2M | $-56.0M | ||
| Q2 25 | $13.9M | $-49.3M | ||
| Q1 25 | $9.1M | $33.6M | ||
| Q4 24 | $34.7M | $-31.6M | ||
| Q3 24 | $21.9M | $-40.5M | ||
| Q2 24 | $1.7M | $-45.5M | ||
| Q1 24 | $3.2M | $-55.5M |
自由现金流PFISRGNX
| Q4 25 | $43.3M | $-52.8M | ||
| Q3 25 | $13.0M | $-56.5M | ||
| Q2 25 | $8.5M | $-49.7M | ||
| Q1 25 | $8.6M | $32.6M | ||
| Q4 24 | $32.1M | $-32.7M | ||
| Q3 24 | $17.6M | $-40.9M | ||
| Q2 24 | $1.3M | $-46.0M | ||
| Q1 24 | $3.0M | $-56.0M |
自由现金流率PFISRGNX
| Q4 25 | 92.7% | -174.0% | ||
| Q3 25 | 27.9% | -189.9% | ||
| Q2 25 | 17.6% | -232.8% | ||
| Q1 25 | 18.7% | 36.6% | ||
| Q4 24 | 72.8% | -154.2% | ||
| Q3 24 | 39.1% | -168.9% | ||
| Q2 24 | 6.0% | -206.2% | ||
| Q1 24 | 13.3% | -358.5% |
资本支出强度PFISRGNX
| Q4 25 | 23.4% | 1.7% | ||
| Q3 25 | 4.7% | 1.7% | ||
| Q2 25 | 11.1% | 1.8% | ||
| Q1 25 | 1.1% | 1.2% | ||
| Q4 24 | 5.8% | 5.1% | ||
| Q3 24 | 9.6% | 1.3% | ||
| Q2 24 | 1.8% | 2.1% | ||
| Q1 24 | 1.0% | 3.6% |
现金转化率PFISRGNX
| Q4 25 | 4.53× | — | ||
| Q3 25 | 1.00× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | 0.60× | 5.53× | ||
| Q4 24 | 5.70× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 0.93× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PFIS
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
